Albany, NY -- (SBWIRE) -- 01/08/2014 -- This updated TMR report provides an overview of advanced "Multiple Sclerosis Drugs Market" Multiple sclerosis (MS) is an inflammation of fatty myelin sheaths around the axons of the brain and spinal cord. MS tends to affect the ability of nerve cells to communicate with each other in the brain and spinal cord. MS affects people with random symptoms based on the location and severity of attack. One event can last for days, weeks or months and can affect any part of the body. Symptoms include imbalance, loss of motor function, spasms, numbness, incontinence, and difficulty in swallowing.
Browse Full Report with TOC: http://www.transparencymarketresearch.com/multiple-sclerosis-drugs.html
There is no known cure for the disease currently and the only drugs available in the market are for delaying the progression of the disease. MS is estimated to affect 2.5 million people worldwide with around 5000 new cases developing each year. The National Multiple Sclerosis Society, Multiple Sclerosis Foundation, Multiple Sclerosis Association of America and several others are organizations which are determined to ensure improvement in the lives of affected people to make them more educated and spread awareness of this disease.
Until the last year, the MS drugs market was led primarily by injectables, yet this trend is changing very quickly to give way to oral MS drugs which is expected to grow strongly beginning from 2013. Gilenya and Aubagio are the top current oral drugs in this segment and Biogen’s oral BG-12 and Teva Laquinimod are two other drugs in the pipeline for approval with a significantly higher efficacy to be launched in the next five years. Although oral MS drugs seem to be growing quickly, it is not expected that they would unsettle injectables anytime soon. Several fatal side effects have been linked to use of Gilenya among those who have a heart disease and thus shows that there is still a long way to go for oral MS drugs. Top contenders in this segment till now are Copaxone, Avonex, Rebif, Betaseron, and Tysabri. Most of these drugs work actively to control MS relapses. Other treatments such as stem-cell transplantation are currently under investigation. The process includes the injection of stem cells which will replace the affected inflamed and diseased cells, greatly improving patient’s quality of life.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
- North America
- Asia Pacific
- Rest of the World
This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
More Reports On Pharmaceutical Market:
About Transparency Market Research (TMR)
Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.
TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information.Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.
90 State Street,
Albany NY - 12207
Browse Market Research Blog: